Proteomic profiling of serum identifies a molecular signature that correlates with clinical outcomes in COPD.
Rania DagherPaul FogelJingya WangDavid SoussanChia-Chien ChiangJennifer KearleyDaniel MuthasCamille TailléPatrick BergerArnaud BourdinCécile ChenivesseSylvie LeroyGary AndersonAlison A HumblesMichel AubierRoland KolbeckMarina Pretolaninull nullPublished in: PloS one (2022)
This study provides insights into COPD heterogeneity and suggests that overexpression of factors involved in lung immunity/host defense, cell fate/repair/ remodelling and mitochondrial/metabolic activities contribute to better clinical outcomes. Hence, high throughput proteomic assay offers a powerful tool for identifying COPD endotypes and facilitating targeted therapies.